Compositions and methods for cancer therapy

A cancer treatment and cancer technology, applied in drug combinations, pharmaceutical formulations, skin cancer vaccines, etc., can solve problems such as limited successful cases

Pending Publication Date: 2021-10-01
AIM IMMUNOTECH INC
View PDF43 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Immunotherapy is a rapidly developing field in the treatment of cancer, but unfortunately it has had limited success

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for cancer therapy
  • Compositions and methods for cancer therapy
  • Compositions and methods for cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0308] Embodiment 1: experimental result

[0309] Currently, surgery is the only potential treatment option for pancreatic cancer, but only about 15 percent of patients are eligible for surgery at initial diagnosis because most pancreatic cancers are detected at an advanced stage of the disease. Approximately 20% of patients were diagnosed with locally advanced pancreatic cancer, and the remaining 65% had metastatic disease.

[0310] The current standard of care (SOC) for locally advanced and metastatic pancreatic cancer is FOLFIRINOX, a four-drug combination therapy with significant toxicity. The approval of FOLFIRJNOX was based on the Phase 2 / 3 ACCORD study published in 2011 (Von Hoff et al., 2011). In this study, FOLFIRINOX was compared with gemcitabine, which was the SOC at the time. The result of the ACOORD study was that overall survival (OS) increased from 6.8 months with gemcitabine to 11.1 months with FOLFIRINOX (p<0.001). However, the complete response rate (CR)...

Embodiment 2

[0337] Example 2: Pancreatic Cancer

[0338] According to the Pancreatic Cancer Action Network, pancreatic cancer is the fourth leading cause of cancer death in the United States. It is the only most common cancer with a five-year survival rate of just 6%. Based on current projections, pancreatic cancer is projected to rise from the fourth leading cause of cancer death in the United States to the second leading cause by 2020. As a result, both new cases and deaths from pancreatic cancer are projected to more than double by 2030 (Matrisian et al., 2012).

[0339] In the European Union, the incidence of pancreatic cancer continues to rise, and the mortality rate is expected to increase by about 30% by 2025, with about 112,000 new cases per year. More specifically, breast cancer deaths were 92,000 in 2010 and 91,000 in 2017, and are expected to reach 90,000 in 2025. Pancreatic cancer, on the other hand, accounted for 76,000 and 91,000 deaths in 2010 and 2017, respectively, a...

Embodiment 3

[0384] Example 3: Melanoma

[0385] with the above use Similar to the example of checkpoint blockers that have shown synergy in the successful treatment of pancreatic cancer, we have also seen positive synergistic antitumor effects in animal models of melanoma.

[0386] The antitumor activity of retamod in combination with an anti-PD-L1 antibody was tested against established subcutaneous B16 melanoma in C57BL / 6 mice. Mice (10 animals per group) were inoculated with 0.4 x 10E6 B16-F10 tumor cells on their shaved posterior flanks. Seven days later (when the largest tumor diameter reached 0.3 to 0.5 cm), the mice were randomly divided into tumor size groups, labeled separately, and assigned to the following six treatment groups:

[0387] No treatment (negative control)

[0388] Retamod 100μg / dose 4X alone,

[0389] Retamod 250μg / dose 4X alone,

[0390] Anti-PD-L1 mAb alone,

[0391] Retamod 100 μg / dose 4X + anti-PD-L1 mAb

[0392] Retamod 250 μg / dose 4X + anti-PD-L1 mA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to the following patent application: Application No. 62 / 885,143, filed August 9, 2019, entitled "Compositions and Methods for the Treatment of Cancer" (Attorney No. 500051-000849) U.S. Provisional Application; U.S. Provisional Application No. 62 / 869,909, filed July 2, 2019, entitled "Synergistic Cancer Compositions and Methods of Using Same," Attorney No. 500051-000820; U.S. Provisional Application No. 62 / 792,760, filed January 15, 2019, entitled "Compositions and Methods for Treating Cancer," (Attorney No. 500051-000766); filed January 15, 2019, and entitled " Compositions and Methods for Treating Cancer" (Attorney No. 500051-000765), U.S. Provisional Application Serial No. 62 / 792,765; ), U.S. Provisional Application Serial No. 62 / 783,834. All publications, patent applications, and patents mentioned in this disclosure are herein incorporated by reference in their entirety...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P35/00A61K31/00A61K39/00
CPCA61P35/00A61K45/06A61K31/713A61P1/18A61P13/12A61K39/39A61K2039/852A61K2039/82A61K2039/876A61K2300/00A61K39/395A61K47/6455A61K31/282A61K31/4745A61K31/513A61K31/519A61K31/7068A61K38/212A61K39/3955
Inventor 大卫·R·斯特雷耶托马斯·K·伊克斯
Owner AIM IMMUNOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap